Canine idiopathic immune-mediated haemolytic anaemia: a review with recommendations for future research.
Idiopathic immune-mediated haemolytic anaemia (IMHA) is one of the most common immune-mediated diseases of dogs. The aim of this article is to review current knowledge of canine IMHA, its etiology, clinical presentation, diagnosis, complications, and treatment, in an attempt to establish why its outcome is still so poor. Clinical signs of anaemia develop within 3 days and dogs present with a median haematocrit of 13%, leucocytosis, a left shift, and reticulocytosis. Coagulation test results support the presence of disseminated intravascular coagulation. About 50% of dogs die in the first 2 weeks after presentation, and analysis of risk factors suggests that mortality is associated with hypercoagulability, inflammatory response, and liver and kidney failure. A positive direct agglutination test, spherocytosis, and true autoagglutination are widely accepted tests to demonstrate anti-erythrocyte antibodies, but are not yet standardized. To date, there is no evidence to support the efficacy of immunomodulators in addition to corticosteroids in the treatment of IMHA. Despite numerous investigations, the prognosis of IMHA remains dismal. There is an urgent need to validate and standardize diagnostic tests and criteria, and clinical trials might benefit from stratifying dogs by mortality risk. Analysis of samples from well-defined cases of canine IMHA might provide insight into the aetiology and pathophysiology of IMHA.
Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, The Netherlands. C.J.Piek@uu.nl
Christine J
CJ
Piek
D000743:Anemia, Hemolytic / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D000818:Animals; D004283:Dog Diseases / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000628:therapy; D004285:Dogs; D056747:Immunomodulation; D011379:Prognosis; D012307:Risk Factors